Gene · 11126
CD160: CD160 molecule
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. CD160: CD160 molecule. Genes, record 11126. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/11126
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| O95971 | CD160 antigen | 181 | 4 | Ensembl, GeneID, HGNC |
Source UniProt
Patents104
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| EP 4806462 A2 | 2026-09-16 | 41 | O95971 | Espacenet |
| EP 4641202 A2 | 2025-10-29 | 4393 | O95971 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 2218 | O95971 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 2219 | O95971 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 14659 | O95971 | Espacenet |
| EP 4619424 A2 | 2025-09-24 | 10 | O95971 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 5764 | O95971 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 5764 | O95971 | Espacenet |
| JP 2025028160 A | 2025-02-28 | 2218 | O95971 | Espacenet |
| JP 2025028160 A | 2025-02-28 | 2219 | O95971 | Espacenet |
1 to 10 of 104
See all 104 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,312
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | CD160 papers | Newest fiscal year |
|---|---|---|---|
| U19AI082630 | Durable Alteration of the Human Immune system after Infection or Immunotherapy | 19 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 12 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 11 | 2025 |
| P01AI039671 | Costimulatory Mechanisms of Autoimmunity | 9 | 2025 |
| P01AI108545 | Synergies among inhibitory receptors in tolerance and disease | 9 | 2025 |
| P51OD011132 | Emory National Primate Research Center | 7 | 2025 |
| P30AI027763 | UCSF-Bay Area Center for AIDS Research | 6 | 2025 |
| P30AI027767 | UAB Center for AIDS Research (CFAR) | 6 | 2025 |
| P30CA016058 | Cancer Center Support Grant | 6 | 2025 |
| P50CA121974 | Yale SPORE in Skin Cancer | 6 | 2025 |
1 to 10 of 1,312Source NIH's project files
See all 1,312 nih grantsPapers2,063
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Mutant HVEM in lymphoma disrupts BTLA and CD160 regulation of anti-tumor signaling. | Front Immunol | 2026 | 42798506 | PubTator, text mining | PubMed |
| Pre-treatment T-cell Transcriptional Signatures Predict Immunotherapy Outcomes in Melanoma. | Res Sq | 2026 | 42687902 | PubTator, text mining | PubMed |
| Proteomic Insights Into Human Induced Regulatory T Cells: The Role of LPXN and CD160 in Immune Suppression. | Mol Cell Proteomics | 2026 | 42624209 | PubTator, text mining | PubMed |
| Immune dysregulation and exhaustion in EBV- associated hemophagocytic lymphohistiocytosis: insights from single-cell transcriptomics and TCR repertoire analysis. | Front Immunol | 2026 | 42620862 | PubTator, text mining | PubMed |
| Ovarian Cancer-Associated Ascites Accumulates NK Lymphocytes Displaying a Transcriptomic Profile Consistent With the Immature/Secretory CD56bright Subtype. | Immunol Cell Biol | 2026 | 42619603 | PubTator, text mining | PubMed |
| Anti-4CB1: A Novel Selective HVEM-Blocking Antibody Enhancing T-Cell and Macrophage Immunity Against Solid Tumors. | Mol Cancer Ther | 2026 | 42617197 | PubTator, text mining | PubMed |
| CD244 overexpression indicates NK cell dysfunction and tumor progression in diffuse large B-cell lymphoma. | Front Immunol | 2026 | 42483169 | PubTator, text mining | PubMed |
| KIF7 promotes the proliferation of clear cell renal cell carcinoma by activating the WNT/β-catenin signaling pathway. | Clin Exp Med | 2026 | 42366250 | PubTator, text mining | PubMed |
| An exploratory integrative analysis of plasma transcriptomic and proteomic predictors of response to total neoadjuvant therapy in locally advanced rectal cancer. | Front Oncol | 2026 | 42339115 | PubTator, text mining | PubMed |
| Polymorphisms in immune checkpoint genes might influence bladder cancer risk and clinical outcome. | Hum Immunol | 2026 | 42284619 | PubTator, text mining | PubMed |
1 to 10 of 2,063
See all 2,063 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/11126
GET https://conductscience.org/api/genes/v1/11126/patents?page=2